Program
delocamten
Also written as “BMS-986435” and “MYK-224”.
Its studies are mostly in Heart Failure · Cardiomyopathy, Hypertrophic, led by Bristol-Myers Squibb.
Furthest: phase 2, since Sep 23, 20229 company-led studies, 2 open or runningNext primary completion: Dec 14, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 92 open or running | phase 2since Sep 23, 2022 | Mar 22, 2022 | Dec 14, 2026phase 2 · NCT06122779 |
- Named in Bristol-Myers Squibb’s own pipeline as
delocamten
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2022First study: phase 1 study in Healthy ParticipantsFirst studyNCT05304533 · 45 enrolled · United States
- Jun 1, 2022Phase 1 study in Healthy VolunteersNCT05405543 · 36 enrolled · United States
- Sep 23, 2022Phase 2 study in Cardiomyopathy, HypertrophicNCT05556343 · 18 enrolled · United States, Italy, Poland and more
- Jan 6, 2023Phase 1 study in Healthy VolunteersNCT05686096 · 7 enrolled · United States
- Nov 3, 2023Phase 2 study in Heart FailureNCT06122779 · 227 enrolled · United States, Argentina, Canada and more
- Jun 21, 2024Phase 1 study in Healthy VolunteersNCT06476821 · 20 enrolled · China
- Aug 27, 2024Phase 1 study in Healthy ParticipantsNCT06577259 · 25 enrolled · United States
- Nov 7, 20252 phase 1 studies in Healthy VolunteersNCT07226817, NCT07248839
Ahead
- Dec 14, 2026Primary completion: phase 2 study in Heart FailureNCT06122779
- Dec 17, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07226817
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07248839Healthy Volunteers · United States | 1 | Completed | Aug 20, 2026 | 69 |
| NCT07226817Healthy Volunteers · United States | 1 | Recruiting | Dec 17, 2026 | 240 |
| NCT06577259Healthy Participants · United States | 1 | Completed | Feb 19, 2025 | 25 |
| NCT06476821Healthy Volunteers · China | 1 | Completed | Oct 11, 2024 | 20 |
| NCT06122779Heart Failure · United States, Argentina, Canada and more | 2 | Active, not recruiting | Dec 14, 2026 | 227 |
| NCT05686096Healthy Volunteers · United States | 1 | Completed | Apr 8, 2023 | 7 |
| NCT05556343Cardiomyopathy, Hypertrophic · United States, Italy, Poland and more | 2 | Terminated | Aug 19, 2024 | 18 |
| NCT05405543Healthy Volunteers · United States | 1 | Completed | Nov 16, 2022 | 36 |
| NCT05304533Healthy Participants · United States | 1 | Completed | Nov 14, 2022 | 45 |
How it is read
Names in the registry
- “BMS-986435”, 5 entries
- “MYK-224”, 4 entries
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Cardiomyopathy, Hypertrophic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.